Chapter Four Hundred and Sixty Seventh: Not Very Good News
Hughes Medical Institute, which is one of the most famous non-profit medical research institutes in the United States, has a global bioterrorism outbreak. Under the coordination of WHO, Hughes Medical Institute has become an 'angel team' to tackle VFV virus specific drugs research institute.
Qiu Xiang led the team towards the conference room.
Qiu Xiang now has a report in his hand, a report on VFV antibody research, but there is not much joy on the faces of everyone.
Antibodies in the patient's serum or body fluids to treat viral infections have been tried and tested and are also the most commonly used. In the research over this period, their team found that the antibodies in the patient's serum were too weak to clear the VFV virus at all.
And they have no way to find patients in the recovery period. The VFV virus is too toxic, and the antibodies produced by the human immune system cannot 'kill' this virus at all.
This has led to the research of their special medicines, and nothing can be done.
After discussion, the team decided to use animal immune serum to try it, and recruited 8 kinds of animals for the experiment to infect the animals with the virus, but it was soon found that even the immunized bovine serum had no obvious effect on the treatment of VFV.
During this time, I was experimenting every day, trying hundreds of possible ways.
After trying all the possible conjectures they discussed, it was finally found that the monoclonal antibody had the greatest chance of success.
In order to speed up the research, the 72-person team was divided into eight groups. Four groups were responsible for finding other therapeutic drugs, and the remaining four groups were responsible for testing the 16 monoclonal antibodies that had been developed. The team led by Qiu Xiang was one of them.
During the test, the four groups of people all used 1,000 times the LD50 (the median lethal dose) to poison the experimental mice.
Within 24 hours after exposure, the mice were injected with monoclonal antibodies, four groups of 16 monoclonal antibodies, and the remaining 11 were effective; 48 hours, 5 antibodies were still effective; 72 hours, only two antibodies remained effective.
It is an antibody studied by the first group led by him, and an antibody studied by the third group led by British medical scientist Judson.
After finding two of the antibodies, they began to experiment with rabbits. After 24 hours, both antibodies were effective; after 48 hours, the ability of the monoclonal antibodies began to show significant differences, and many lost their activity. getting weaker.
The incubation period of VFV virus is far longer than this time. Such antibodies cannot be used for treatment at all, and research has come to a standstill again.
Finally, after everyone's discussion, it was decided to adopt the 'cocktail' method of EBOR's special drug research, using a mixture of 4 monoclonal antibodies with the best effect, and using a virus that can produce human interferon as the adjuvant of the "cocktail" antibody , so that the 'cocktail' can still function 72 hours after exposure.
And the 'cocktail' potion was named AG72 by them.
Now, the test results of AG72 are in Qiu Xiang's hands.
Looking at the report in his hand, he was not happy because the result was different from what they had imagined.
When Qiu Xiang, Judson and others entered the conference room, they felt dozens of pairs of eyes falling on them. Many researchers on the field did not look very good. Since the formation of the 72-person team, their research has made some progress, but it has not progressed much. Now all hope is on the report in the hands of Qiu Xiang and Judson.
"Come on." Qiu wanted to hand Judson the report in his hand.
"You come." Judson shook his head without reaching out to take it.
Qiu Xiang nodded helplessly, and after everyone was seated, he asked his assistant to send the report in his hand to every researcher on the field, and then he stepped onto the podium.
"The results of the monoclonal antibody test came out, which were different from what we predicted. We tested the effect of AG72 with two rhesus monkeys. On day 4 of infection, the monkeys developed symptoms, and as planned, they were injected with AG72. But unfortunately, the virus in the monkey has not disappeared, and VFV has not been cured." Qiu Xiang's voice was heavy.
There was a sigh in the conference room, and many experts shook their heads and frowned.
Monoclonal antibodies are the most promising direction for success in a short period of time. If monoclonal antibodies fail, it will take longer for effective drugs to appear.
Now the number of people infected with VFV virus in the world has reached more than 26,000, and this number is refreshing every day, and the death toll has soared to 2,378, and there is no cure for the time being. If the drug does not come out, it means that the number of deaths will increase.
"But there's not-so-good news."
The crowd instantly cheered up, pricked up their ears and waited for Qiu Xiang's answer.
"The rhesus monkeys injected with AG72 did not further deteriorate within a week. AG72 cannot cure VFV, but it can inhibit the metabolism of VFV and control the further deterioration of the disease. This result can give the disease more time for treatment. ."
Many people on the field applauded excitedly and cried with joy. At this time, any small piece of good news is inspiring good news.
The "Angel Team" made a breakthrough in the VFV virus specific drug, and successfully developed a monoclonal antibody drug that inhibits the deterioration of VFV disease.
When the news was released, it spread like crazy to all corners of the world, arousing the excitement of the whole people.
Now is the most serious period of the VFV virus, in a time of global panic, the biological virus has almost reached the critical point of completely out of control. At this time, the good news from the 72-man team is undoubtedly the most exciting time.
The victory in the fight against the biological war has dawned.
When the outside world cheered the results of the 72-member team, there was the same happy event in another corner.
Jianghe Institute of Microbiology Medicine.
Xu Minsheng had a rare smile on his face.
After Jangho and Lanhong Pharma were merged by Army Ant Group and reorganized into Jangho Pharma, he became one of the team leaders of Jangho Pharma's pharmaceutical development team, responsible for the development of tumor vaccines.
The current headquarters of Jangho Pharma is the main research institute of microbiological medicine of Haixing Company, and the main drugs of Haixing Company are all developed from here.
Some time ago, Chen Mo contacted them, told them a research direction, and also gave them some information, so that the team of their research institute could make medicines related to the data. The medicines may reduce the activity of VFV virus and help VFV treatment.
Now is the most terrifying time when the VFV virus is raging. Under the order of Chen Mo, the entire team of the institute immediately convened personnel to start the development of drugs.
The team concentrated the strength of the elites of the entire research institute, thoroughly understood the information given by Chen Mo, worked in shifts to study, and finally made progress.
During this period, I contacted Chen Mo several times and asked some questions about the research direction. After several major breakthroughs, I finally completed the required medicine according to Chen Mo's meaning.
They named the drug they developed HX3.
Now the VFV virus in the petri dish, after adding the HX3 agent, the metabolic activity is significantly reduced within 24 hours, and the agent has met the requirements of Chen Mo.
"Success." Xu Minsheng showed a rare smile.
"Success." Several researchers around also nodded and took a deep breath.
"You will sort out the report and give it to the boss. I'll ask the boss what to do with HX3 next." After speaking, Xu Minsheng turned and left the laboratory.
https://
Please remember this book's first domain name: . Mobile version reading website: